How to treat uneven skin tone — a strategic approach.

"Uneven skin tone" is one of the most commonly cited skincare concerns, and one of the most poorly defined. The phrase is used as shorthand for a range of visually similar but mechanistically different conditions: post-inflammatory hyperpigmentation, melasma, solar lentigines, and general dullness all appear as tone irregularities, and all respond differently to treatment.

A brightening routine that addresses one of these may have limited effect on another. The strategic question is not what to use — it is which condition is driving the appearance.

Four distinct causes

Post-inflammatory hyperpigmentation (PIH). Melanin over-deposition following a healed inflammatory event — an acne lesion, a contact reaction, or any wound to the skin. The melanocytes in and around the site of inflammation become hyperactive during healing and deposit excess melanin. PIH appears as flat, darker patches that roughly correspond to the location of the original lesion. It is prevalent across all skin types but more pronounced in Fitzpatrick skin types III–VI, where baseline melanocytic activity is higher and the inflammatory response more robustly pigmented.

Melasma. Chronically elevated melanocyte activity driven primarily by UV exposure and hormonal signalling — oestrogen and progesterone sensitise melanocytes to UV stimulation, which is why melasma is more common in people using oral contraceptives, during pregnancy, or during hormone therapy. It presents as larger, symmetric areas of hyperpigmentation, typically across the cheeks, forehead, upper lip, and bridge of the nose. UV exposure reliably triggers and worsens it; treatment without rigorous sun protection does not hold.

Solar lentigines. Discrete, flat, brown spots from years of cumulative UV exposure. They are a feature of photoageing rather than acute inflammation. They tend to appear on the face, hands, chest, and arms. They are stable once formed and respond more slowly to topical treatment than PIH — and more reliably to professional treatments such as IPL or laser.

Diffuse dullness. Not technically a pigmentation condition, but often grouped under "uneven tone" because it creates the same visual impression. Dullness results from the accumulation of dead corneocytes on the skin's surface, light reflecting unevenly from their dry, irregular surfaces rather than from the smoother surface of renewed skin. It is addressed by exfoliation and cellular turnover — not by targeting melanogenesis.

The strategy

The most reliable framework is to identify which component dominates, and ensure the routine is actually targeting it.

SPF first, unconditionally. UV drives every pigmentation mechanism listed above — it triggers melasma acutely, worsens PIH, and generates solar lentigines over time. Daily broad-spectrum SPF is not supplementary to a brightening routine; it is the most impactful single intervention in it. Without consistent sun protection, topical actives are working against an ongoing stimulus.

For PIH: The evidence-based approach is to block multiple points in the melanogenesis pathway: niacinamide (inhibits melanosome transfer from melanocytes to keratinocytes); vitamin C (tyrosinase inhibition and antioxidant activity); azelaic acid (tyrosinase inhibition, selective cytotoxicity on hyperactive melanocytes, anti-inflammatory); tranexamic acid (upstream plasmin signalling blockade). These address different steps and are genuinely additive. Exfoliating acids accelerate the shedding of melanin-loaded corneocytes from the surface. Retinoids increase cell turnover and stimulate collagen synthesis with long-term benefit for overall tone.

Timeline: mild PIH, 8–16 weeks with consistent active treatment. Moderate PIH, 16–24 weeks. Darker skin tones may require longer trials before results are visible.

For melasma: Sun protection is non-negotiable and must be rigorous — reapplied every two hours outdoors, worn every day regardless of indoor or outdoor time. The same topical actives used for PIH apply, with particular evidence for azelaic acid at 15–20% prescription strength and combination formulations containing hydroquinone, tretinoin, and a corticosteroid (triple therapy, prescription-only) for severe cases. If hormonal contraception is a confirmed trigger, discussing alternatives with a GP is relevant — melasma will continue to recur with ongoing hormonal stimulation regardless of topical treatment.

For solar lentigines: Topical approaches apply — vitamin C, niacinamide, azelaic acid — with AHA exfoliation to support cell turnover. Established, flat sun spots respond slowly to topicals. Professional treatments (intense pulsed light, pigment laser, cryotherapy) are substantially more efficient for discrete spots. These are a case where topicals are maintenance and prevention rather than primary treatment.

For diffuse dullness: Exfoliation. AHAs (glycolic, lactic) or BHAs (salicylic) at two to three times weekly remove the dead-cell accumulation that scatters light. Retinoids increase cell turnover structurally over months. Consistent hydration — a barrier-supportive moisturiser — improves the reflective quality of the skin surface. No brightening serum addresses dullness caused by cellular accumulation.

What does not work

Scrubbing harder. Physical exfoliation can generate micro-inflammation that causes PIH in reactive skin, adding the very condition it is attempting to address.

DIY lemon juice or raw citrus on the skin. Citric acid is a mild AHA, but furanocoumarins in lemon juice are potent photosensitisers — applied topically and exposed to UV, they can generate severe PIH or phototoxic burns, paradoxically worsening the condition.

Single-ingredient brightening wipes or sheet masks. Most actives require sustained contact time to penetrate and act — the brief contact of a wipe delivers negligible active concentration to the skin.

The consistent principle

Uneven skin tone improves with targeted, consistent intervention over months — not rapid treatment over weeks. The most common reason a routine fails is either targeting the wrong mechanism or losing patience before the treatment timeline has elapsed.

The skin's pigmentary response to both UV and inflammation is slow and cumulative in each direction. Acquiring hyperpigmentation takes months of UV exposure or repeated inflammation. Reversing it takes similar timescales. The most reliable outcomes come from treating the correct condition with evidence-based actives, protecting from UV without exception, and maintaining both for long enough to see the result.